Related Experiment Videos
An overview of thrombolytic agents
1Center for Research in Thrombolysis, Brigham and Women's Hospital, Boston.
Chest
|April 1, 1990
Summary
Thrombolytic therapy, including streptokinase and urokinase, effectively lyses fibrin clots in acute myocardial infarction. This review details thrombus development and the mechanisms of action for available thrombolytic agents.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Thrombolytic therapy use has significantly increased for acute myocardial infarction.
- Available agents include streptokinase, urokinase, tissue-type plasminogen activator, and single-chain urokinase-type plasminogen activator.
- These agents activate plasminogen through diverse mechanisms to lyse fibrin clots.
Purpose of the Study:
- To review the mechanisms of pathophysiologic thrombus development.
- To discuss available pharmacologic agents for thrombus lysis.
- To explain the mechanisms of action of these thrombolytic agents.
Main Methods:
- Literature review of thrombolytic therapy mechanisms.
- Analysis of thrombus formation pathways.
- Pharmacological review of fibrinolytic agents.
Main Results:
- Thrombolytic agents exhibit varied mechanisms for plasminogen activation and clot lysis.
- Understanding these mechanisms is crucial for effective treatment of thrombotic events.
- The article provides a comprehensive overview of current thrombolytic strategies.
Conclusions:
- Thrombolytic therapy is a vital treatment for acute myocardial infarction.
- Diverse agents offer different mechanisms for fibrin clot dissolution.
- This review synthesizes key information on thrombolysis for clinical and research purposes.